SanBio, Inc., a Tokyo, Japan, and Mountain View, California-based scientific leader in regenerative medicine for neurological disorders, has been awarded a $20m grant from the California Institute of Regenerative Medicine (CIRM).
The grant will support the company’s Phase 2b clinical trial for the treatment of chronic stroke (ACTIsSIMA), jointly sponsored with Sunovion Pharmaceuticals Inc.
Led by Keita Mori, CEO, and Dr. Damien Bates, Chief Medical Officer and Head of Research, SanBio SanBio is a regenerative medicine company with cell-based products in various stages of research, development, and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke with its joint development partner, Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada. The company is also implementing a global Phase 2 clinical trial in the United States and Japan using SB623 for treatment of motor impairment resulting from traumatic brain injury.
FinSMEs
05/07/2017